We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The UK’s drug pricing watchdog has recommended reimbursement for Eli Lilly’s lung cancer drug Alimta and Pfizer’s leukemia therapy Bosulif at discounted prices. Read More
Pfizer is advancing talks to acquire the U.S. cancer drug company Medivation for close to $14 billion in an effort to boost its oncology portfolio. Read More
The U.S. Judicial Panel on Multidistrict Litigation is consolidating price-fixing suits against generics makers Covis Pharmaceuticals’ heart drug Lanoxin in Pennsylvania federal court. Read More
Healthcare providers spent $121 billion on prescription drugs covered under the Medicare Part D program in 2014, representing a 12.6 rise in spending from 2013. Read More
A federal judge rendered Janssen’s composition patent for Remicade invalid, marking a loss for the company engaged in ongoing efforts to block biosimilar competition. Read More
The UK’s drug pricing watchdog has recommended that the National Health Service reimburse Pfizer lung cancer drug Xalkori, while rejecting to refund Novartis’ breast cancer therapy Everolimus and Janssen’s non-Hodgkin’s lymphoma drug Imbruvica. Read More
Investment firms T. Rowe and Alleghany have filed a suit against Valeant and six executives over the company’s sales strategy that involved price gouging and acquisitions, claiming those tactics cost investors billions. Read More